Specify a stock or a cryptocurrency in the search bar to get a summary
MaxCyte Inc
MXCTMaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. Address: 9713 Key West Avenue, Rockville, MD, United States, 20850
Analytics
WallStreet Target Price
9.25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MXCT
Dividend Analytics MXCT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MXCT
Stock Valuation MXCT
Financials MXCT
Results | 2019 | Dynamics |